On Apr. 2, 2020, Emergent BioSolutions announced it has entered into a formal partnership with the U.S. government to expedite development of a plasma-derived therapy for patients with coronavirus disease 2019 (COVID-19).

Emergent has received $14.5 million from the BARDA in support of its COVID-HIG program, one of two hyperimmune development programs announced by Emergent in March.